英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • TALZENNA Plus XTANDI Significantly Improves Radiographic . . .
    Prostate cancer is the second most common cancer in men worldwide, with an estimated 1 4 million new cases diagnosed globally in 2022 1 and 330,000 new cases anticipated in the United States in 2026 2 mCSPC, is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen inhibition 3 Despite recent
  • Niraparib and abiraterone acetate plus prednisone for HRR . . .
    We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Metastatic prostate cancer happens when the cancer spreads from the prostate to other parts of the body Sometimes the cancer spreads and hormone therapy helps control it This is called metastatic castration-sensitive prostate cancer (mCSPC) If the cancer spreads and no longer responds to hormone therapy medicines, it's considered mCRPC
  • CUA Call-to-Action: Advanced Prostate Cancer (mCSPC) – 2026 . . .
    Apply the latest guideline recommendations and evidence to optimize disease characterization and treatment selection in mCSPC Integrate advanced imaging, biomarker, and genetic testing into clinical decision-making to personalize therapy
  • Treatment Patterns in Advanced Prostate Cancer from . . .
    How does genetic testing at diagnosis influence your treatment decisions around therapy intensification in mCSPC? Led by the moderator, the multidisciplinary panelists examine how treatment patterns in advanced prostate cancer have shifted from widespread ADT monotherapy toward increasing use of doublet and triplet therapy, supported by real
  • Phase III Study: Saruparib Combo w. . . | Advanced Prostate. . .
    The safety and efficacy of saruparib plus new hormonal agents for the treatment of mCSPC and mCRPC are being assessed in the Phase I IIa PETRANHA study (NCT05367440), with the initial data indicated that saruparib (60 mg QD) can be safely combined with enzalutamide, abiraterone acetate, or darolutamide
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Advanced Prostate Cancer: AUA SUO Guideline (2026)
    The management of advanced prostate cancer is rapidly evolving To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer





中文字典-英文字典  2005-2009